Alteon begins Phase IIb

ALT began a 450-patient, U.S. Phase IIb trial of ALT-711 advanced glycosylation end-product (A.G.E.) crosslink breaker to treat isolated systolic hypertension. The SAPPHIRE (Systolic And Pulse Pressur...